The latest decline reflects continued caution following FY2026 results in September, when Genus reported a 35% rise in adjusted profit before tax and a £60 million buyback, but forecast only moderate growth in FY2027 weighted towards the second half. The shares fell around 6.5% …
Key sector variables include clinical or product milestones, reimbursement, regulatory pathways and commercial uptake. Investors may respond differently to progress on individual projects and evidence of recurring earnings.
Key sector variables include clinical or product milestones, reimbursement, regulatory pathways and commercial uptake. Investors may respond differently to progress on individual projects and evidence of recurring earnings.
Key sector variables include clinical or product milestones, reimbursement, regulatory pathways and commercial uptake. Investors may respond differently to progress on individual projects and evidence of recurring earnings.
Key sector variables include clinical or product milestones, reimbursement, regulatory pathways and commercial uptake. Investors may respond differently to progress on individual projects and evidence of recurring earnings.
Key sector variables include clinical or product milestones, reimbursement, regulatory pathways and commercial uptake. Investors may respond differently to progress on individual projects and evidence of recurring earnings.
Key sector variables include clinical or product milestones, reimbursement, regulatory pathways and commercial uptake. Investors may respond differently to progress on individual projects and evidence of recurring earnings.
The headline numbers explain the enthusiasm. Pretax profit rose 22% in the quarter, whileRevenuegrew by between 6.7% and 7%, depending on the measure reported. Management also reaffirmed its full-year guidance, which gave investors reassurance that the good quarter was not a one-off and that …
GSK is one of Britain's largest drugmakers, with aBusinessbuilt around prescription medicines and vaccines. Companies of this type are often treated as defensive holdings becauseDemandfor medicines is less sensitive to the economic cycle than demand for many other goods and services. That reputation tends …
The selection spans FTSE-listed businesses and AIM growth candidates rather than a ranking by daily price gains.